This website uses cookies to enhance the user experience.
C

CALLUNA PHARMA AS932 255 189

Research
Limited company
Gaustadalléen 21 0349 OSLO, Norge

CALLUNA PHARMA AS

Keywords

researchdevelopment workbiotechnologygenomicspharmageneticsgene samplesdna sequencingdna synthesisdna deepeninggenetic engineeringproteinsmoleculespeptide sequencinglipidglycotechniqueproteomicshormonesgrowth factorscell receptorspheromonescell culturetissue culturecrossingcell fusionvaccineimmunostimulatorsembryo manipulationprocess biotechnologybioreactorsfermentationbioprocessingbiorecoverybiodesulfurizationbiological pulp productionbiofiltrationbiological regenerationsubcellular organismsgene therapyvirusesvectors

Organization

Chairman of the board
Years since formation
2 years
since Oct 14, 2023
Type
Limited company
VAT registered
Yes
Number of employees
9

Ownership

Number of shares and share classes
74,167,000
3 share classes
Total number of shareholders
6
3 companies, 3 persons
Belongs to group of

Financials

Total operating income 2024
26,904,988
NOK
Annual total result 2024
-11,910,670
NOK
Total equity 2024
769,267,140
NOK
Last update: Jul 28, 2025

Management

Management / administration

NameRoleShares
Managing Director/CEO-

Board

NameRoleShares
Board Member-
Board Member-
Board Member-
Board Member-
ResignedBoard Member-
Chairman-
Board Member-

Others

NameRoleShares
D
DYNAMIK SMART ACCOUNTING AS
Accountant-
B
BJØRGVIN REVISJON AS
Auditor-
Last update: Apr 10, 2025

Ownership

Company shareholders

NameShare classTotal number of sharesShare
C
CALLUNA PHARMA POOLCO AS
Ordinary shares
33,867,000
45.66 %
Ordinary shares
27,422,185
36.97 %
Ordinary shares
8,300,000
11.19 %
Extraordinary shares
3,463,451
4.67 %
C
CALLUNA PHARMA POOLCO AS
Extraordinary shares
687,056
0.93 %
C
CALLUNA PHARMA POOLCO AS
J-shares
427,308
0.58 %

Shares owned by the CALLUNA PHARMA AS

NameShare classTotal number of sharesShare
A
ARXX THERAPEUTICS AS
Ordinary shares
26,043,511
100 %
Last update: Jun 2, 2025

Group structure

  • Total operating income 2024: NOK 26,904,988
    Operating profit 2024: NOK -26,638,063
    Employees: 9

Financials

in NOK

Summary

Year2023
Total operating income
26,904,988
Annual Total Result
-11,910,670
Total assets
853,584,265
Total liabilities
84,317,125
Total equity
769,267,140

P&L

Year2023
Total operating income
26,904,988
Total operating costs
53,543,051
Operating result
-26,638,063
Financial income/costs
14,727,394
Profit before tax
-11,910,670
Total tax & extraordinary income/cost
0
Annual Total Result
-11,910,670

Balance overview

Year2023
Total fixed assets
645,315,226
Total current assets
208,269,039
Total assets
853,584,265
Short term debt
84,317,125
Long term debt
0
Total liabilities
84,317,125
Contributed capital
769,267,140
Retained earnings
0
Total equity
769,267,140
Total equity and liabilities
853,584,265

Classification

Category
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises
Standard industrial classification
M
Main industrial area
Professional, scientific and technical activities
72
Activity
Scientific research and development
72.1
Main industrial group
Research and experimental development on natural sciences and engineering
72.11
Industrial group
Research and experimental development on biotechnology
72.110
Industrial group
Research and experimental development on biotechnology